Forest To Test Alzheimer’s Drug Neramexane As Monotherapy in Phase II/III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The NMDA receptor agonist failed to show efficacy as a combination therapy with acetylcholinesterase inhibitors in pivotal trial for moderate-to-severe disease, Forest says.